 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical...

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...

Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line...

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ( Dyadic , or the Company ) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Present at Industry Events in November

JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ( Dyadic , we , us , our , or the Company ) (NASDAQ: DYAI), a global biotechnology company focused on building...

Dyadic Appoints Doug Pace to Its Executive Leadership Team

JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ( Dyadic , we , us , our , or the Company ) (NASDAQ: DYAI), a global biotechnology company focused on building...

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ( VIC ) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ( Dyadic , or the Company ) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Present at Industry and Investor Events in October

JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ( Dyadic ) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and...

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ( Dyadic , or the Company ) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Present at BioProcess International

Dyadic International, Inc. (NASDAQ:DYAI  Get Free Report) shares passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.86 and traded...

Dyadic International (NASDAQ:DYAI) Shares Pass Below 50 Day Moving Average of $1.86

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Watchers	1,821
52-Wk Low	$1.12
52-Wk High	$2.40

Market Cap	$74.33M
Volume (M)	22,178.00
52-Wk High	$2.40
52-Wk Low	$1.12

DYAI Dyadic International Inc., DE

About

Feed

News

Sentiment

Earnings

Fundamentals